# Click Activated Protodrugs Against Cancer: local capture and activation of capped chemotherapy by a tetrazine biopolymer

Source: https://onco.cc/key-papers/paper-wu-click-activated-protodrugs-local-capture-chem-sci-2021/  
OnCo record `paper-wu-click-activated-protodrugs-local-capture-chem-sci-2021` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The chemistry paper behind SQ3370. It describes the injected biopolymer and four capped chemotherapy drugs, and explains why the doxorubicin one, SQP33, was taken forward.

## Summary

From the University at Albany and Shasqi, this paper sets out the platform: a tetrazine-modified sodium hyaluronate biopolymer injected at a tumour, then systemic doses of a trans-cyclooctene (TCO)-modified cytotoxic prodrug of attenuated activity. The prodrug is captured by the biopolymer through an inverse electron-demand Diels-Alder reaction between tetrazine and TCO and then converted to the active drug at the site, independent of biomarker expression, enzymatic activity, pH or oxygen level.

TCO-modified forms of doxorubicin, paclitaxel, etoposide and gemcitabine were made. On cytotoxicity, solubility, stability and activation in the laboratory, the doxorubicin prodrug SQP33 was the most promising. In mice, the maximum tolerated dose of SQP33 with locally injected biopolymer (SQL70) was 19.1 times that of conventional doxorubicin. In rats, one injection of SQL70 captured several SQP33 doses given cumulatively at 10.8 times the maximum tolerated dose of conventional doxorubicin, with greatly reduced systemic toxicity. The combination, named SQ3370, showed anti-tumour activity in a syngeneic mouse model.

## Fields

- Kind: Key paper
- Last checked: 2026-11-16
- Also known as: Click activated protodrugs against cancer increase the therapeutic potential of chemotherapy through local capture and activation
- Journal: Chemical Science
- Year: 2021
- DOI: 10.1039/d0sc06099b
- Authors: Wu K, Yee NA, Srinivasan S, et al.
- Findings: Four cytotoxic drugs (doxorubicin, paclitaxel, etoposide, gemcitabine) were made as TCO-modified prodrugs; the doxorubicin prodrug SQP33 was selected.; In mice, the maximum tolerated dose of SQP33 with the injected biopolymer SQL70 was 19.1 times that of conventional doxorubicin.; In rats, a single SQL70 injection captured multiple SQP33 doses given cumulatively at 10.8 times the maximum tolerated dose of conventional doxorubicin.
- What it means: It names the two components of SQ3370 and the reaction that joins them, and shows the design is modular: the same activator can switch on different capped drugs.
- Caveats: Laboratory and animal work only; figures are from the abstract.; A correction notice was published for this paper (10.1039/d1sc90098f); its content was not read.

## Sources

- Chem Sci 2021: https://doi.org/10.1039/d0sc06099b
- PubMed: https://pubmed.ncbi.nlm.nih.gov/34163888/
- Europe PMC (free full text): https://europepmc.org/article/MED/34163888

## Connected records

- technologies: [Click-activated prodrugs (bioorthogonal drug activation in the body)](https://onco.cc/technologies/click-activated-prodrugs/)
- drugs: [SQ3370](https://onco.cc/drugs/sq3370/)
- companies: [Shasqi](https://onco.cc/companies/shasqi/)

---
JSON: https://onco.cc/api/v1/entities/paper-wu-click-activated-protodrugs-local-capture-chem-sci-2021.json